Literature DB >> 31712913

What is the most useful body composition parameter for predicting toxicities of preoperative chemotherapy for gastric cancer?

Tadayoshi Hashimoto1, Yukinori Kurokawa2, Tsuyoshi Takahashi1, Takuro Saito1, Kotaro Yamashita1, Koji Tanaka1, Tomoki Makino1, Makoto Yamasaki1, Masaaki Motoori1,3, Yutaka Kimura1,4, Kiyokazu Nakajima1, Masaki Mori5, Yuichiro Doki1.   

Abstract

PURPOSE: Preoperative chemotherapy is an effective treatment option for resectable gastric cancer, but it is associated with various adverse events (AEs). This study aimed to identify the body composition parameters that most accurately predicted the incidence of AEs in preoperative chemotherapy for gastric cancer.
METHODS: The present study included a total of 114 patients who received preoperative chemotherapy for resectable gastric cancer. We estimated various body composition parameters using computed tomography images obtained before preoperative chemotherapy. Their associations with the incidence of hematological (grade ≥ 3) and non-hematological (grade ≥ 2) AEs were analyzed by multivariate logistic regression analyses.
RESULTS: Seventy-two of the 114 (63.2%) patients experienced hematological AEs (grade ≥ 3), specifically neutropenia in 68 (59.6%), anemia in 5 (4.9%), and thrombocytopenia in 3 (2.6%). Meanwhile, 59 patients (51.8%) experienced non-hematological AEs (grade ≥ 2), namely hypoalbuminemia in 31 (27.2%), anorexia in 24 (21.1%), and febrile neutropenia in 17 (14.9%). Multivariate analyses revealed that a low psoas muscle index (PMI) was an independent risk factor for the incidence of both hematological and non-hematological AEs.
CONCLUSIONS: Patients with a low PMI experienced an increased incidence of hematological and non-hematological toxicities during preoperative chemotherapy for gastric cancer. Clinicians should be aware of these risks in this population.

Entities:  

Keywords:  Body composition parameters; Chemotherapeutic toxicity; Gastric cancer; Preoperative chemotherapy; Psoas muscle index

Year:  2019        PMID: 31712913     DOI: 10.1007/s00595-019-01915-5

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  32 in total

1.  Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.

Authors:  Rachna Raman; Sarah L Mott; Mary C Schroeder; Sneha Phadke; Jad El Masri; Alexandra Thomas
Journal:  Clin Breast Cancer       Date:  2016-06-23       Impact factor: 3.225

2.  Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy.

Authors:  J Alexandre; M Gross-Goupil; B Falissard; M-L Nguyen; J-M Gornet; J-L Misset; F Goldwasser
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

3.  Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.

Authors:  Poorna Anandavadivelan; Torkel B Brismar; Magnus Nilsson; Asif M Johar; Lena Martin
Journal:  Clin Nutr       Date:  2015-05-27       Impact factor: 7.324

Review 4.  Influence of obesity on drug disposition.

Authors:  R A Blouin; J H Kolpek; H J Mann
Journal:  Clin Pharm       Date:  1987-09

5.  Sarcopenia is predictive of nosocomial infection in care of the elderly.

Authors:  Gaëlle Cosquéric; Aline Sebag; Cyril Ducolombier; Caroline Thomas; François Piette; Sébastien Weill-Engerer
Journal:  Br J Nutr       Date:  2006-11       Impact factor: 3.718

6.  The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.

Authors:  Alex Farr; Myriam Stolz; Lukas Baumann; Zsuzsanna Bago-Horvath; Elisabeth Oppolzer; Georg Pfeiler; Michael Seifert; Christian F Singer
Journal:  Breast       Date:  2017-04-07       Impact factor: 4.380

7.  Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.

Authors:  S Antoun; V E Baracos; L Birdsell; B Escudier; M B Sawyer
Journal:  Ann Oncol       Date:  2010-01-20       Impact factor: 32.976

8.  Low Muscularity and Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for Colorectal Cancer.

Authors:  George Malietzis; Neil Johns; Hafid O Al-Hassi; Stella C Knight; Robin H Kennedy; Kenneth C H Fearon; Omer Aziz; John T Jenkins
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

9.  Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.

Authors:  Olivier Mir; Romain Coriat; Benoit Blanchet; Jean-Philippe Durand; Pascaline Boudou-Rouquette; Judith Michels; Stanislas Ropert; Michel Vidal; Stanislas Pol; Stanislas Chaussade; François Goldwasser
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

10.  Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.

Authors:  Willemieke P M Dijksterhuis; Maarten J Pruijt; Stephanie O van der Woude; Remy Klaassen; Sophie A Kurk; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-01-21       Impact factor: 12.910

View more
  3 in total

1.  Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors.

Authors:  Emir Celik; Veysel Suzan; Nilay Sengul Samanci; Aysegul Akkan Suzan; Mehmet Karadag; Serdar Sahin; Muhammed Samil Aslan; Hakan Yavuzer; Nebi Serkan Demirci; Alper Doventas; Fuat Hulusi Demirelli
Journal:  Eur Geriatr Med       Date:  2021-11-26       Impact factor: 1.710

2.  Impact of the first era of the coronavirus disease 2019 pandemic on gastric cancer patients: a single-institutional analysis in Japan.

Authors:  Shohei Fujita; Shinichi Sakuramoto; Yutaka Miyawaki; Yosuke Morimoto; Gen Ebara; Keiji Nishibeppu; Shuichiro Oya; Shiro Fujihata; Seigi Lee; Hirofumi Sugita; Hiroshi Sato; Keishi Yamashita
Journal:  Int J Clin Oncol       Date:  2022-03-28       Impact factor: 3.850

3.  How can sarcopenia be prevented after gastrointestinal surgery?

Authors:  Yukinori Kurokawa
Journal:  Ann Gastroenterol Surg       Date:  2022-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.